Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.19.3
Subsequent Events (Details) - USD ($)
$ in Millions
1 Months Ended 9 Months Ended
Oct. 31, 2019
Jan. 31, 2019
Sep. 30, 2019
Subsequent Event [Line Items]      
Approximate medicine approval decision term     60 days
Grifols      
Subsequent Event [Line Items]      
Upfront payment received   $ 30.0 $ 5.0
Grifols | fostamatinib | Upon EMA approval of fostamatinib for treatment of chronic ITP      
Subsequent Event [Line Items]      
Contingent payments $ 20.0 $ 20.0  
Subsequent event | Medison Pharma | fostamatinib      
Subsequent Event [Line Items]      
Upfront payment received $ 5.0